Jaime F Modiano

List of Publications by Year
in descending order

176 papers	6,741 citations	57758 44 h-index	76900 74 g-index
186 all docs	186 docs citations	186 times ranked	6490 citing authors

#	Article	IF	Citations
1	Rethinking dog domestication by integrating genetics, archeology, and biogeography. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8878-8883.	7.1	412
2	Diagnosis of Canine Lymphoid Neoplasia Using Clonal Rearrangements of Antigen Receptor Genes. Veterinary Pathology, 2003, 40, 32-41.	1.7	293
3	The dog as a cancer model. Nature Biotechnology, 2006, 24, 1065-1066.	17.5	290
4	A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nature Genetics, 2015, 47, 615-624.	21.4	207
5	Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans â€“ man and his best friend share more than companionship. Chromosome Research, 2008, 16, 145-154.	2.2	193
6	NFATc2-Mediated Repression of Cyclin-Dependent Kinase 4 Expression. Molecular Cell, 2002, 10, 1071-1081.	9.7	176
7	Distinct B-Cell and T-Cell Lymphoproliferative Disease Prevalence among Dog Breeds Indicates Heritable Risk. Cancer Research, 2005, 65, 5654-5661.	0.9	160
8	Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B. Genome Biology, 2013, 14, R132.	9.6	132
9	Artemisinin Blocks Prostate Cancer Growth and Cell Cycle Progression by Disrupting Sp1 Interactions with the Cyclin-dependent Kinase-4 (CDK4) Promoter and Inhibiting CDK4 Gene Expression. Journal of Biological Chemistry, 2009, 284, 2203-2213.	3.4	128
10	Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma. Bone, 2012, 50, 171-181.	2.9	122
11	Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. Bone, 2011, 49, 356-367.	2.9	117
12	Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Experimental Hematology, 2006, 34, 870-878.	0.4	116
13	Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. Veterinary Immunology and Immunopathology, 2014, 159, 192-201.	1.2	113
14	Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial. , 2017, 5, 98.		101
15	Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma. Cancer Research, 2018, 78, 326-337.	0.9	100
16	Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background. Genome Research, 2015, 25, 1634-1645.	5.5	96
17	Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Laboratory Investigation, 2004, 84, 562-572.	3.7	95
18	Molecular Profiling Reveals Prognostically Significant Subtypes of Canine Lymphoma. Veterinary Pathology, 2013, 50, 693-703.	1.7	95

#	Article	IF	Citations
19	Expression and Significance of p53, Rb, p21/waf-1, p16/ink-4a, and PTEN Tumor Suppressors in Canine Melanoma. Veterinary Pathology, 2002, 39, 458-472.	1.7	94
20	Refining tumor-associated aneuploidy through â€˜genomic recodingâ€™ of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas. Leukemia and Lymphoma, 2011, 52, 1321-1335.	1.3	89
21	MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma. Orphanet Journal of Rare Diseases, 2013, 8, 7.	2.7	89
22	Canine cancer immunotherapy studies: linking mouse and human. , 2016, 4, 97.		86
23	Targeting of Beta Adrenergic Receptors Results in Therapeutic Efficacy against Models of Hemangioendothelioma and Angiosarcoma. PLoS ONE, 2013, 8, e60021.	2.5	80
24	Gene Expression Profiles of Sporadic Canine Hemangiosarcoma Are Uniquely Associated with Breed. PLoS ONE, 2009, 4, e5549.	2.5	80
25	Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study. PLoS ONE, 2014, 9, e87585.	2.5	79
26	SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma. Cancer Research, 2018, 78, 3421-3431.	0.9	76
27	CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma. Veterinary Pathology, 2005, 42, 468-476.	1.7	75
28	Influence of genetic background on tumor karyotypes: Evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma. Chromosome Research, 2009, 17, 365-377.	2.2	74
29	Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma. Molecular Cancer Research, 2019, 17, 2410-2421.	3.4	72
30	Mutations of Phosphatase and Tensin Homolog Deleted from Chromosome 10 in Canine Hemangiosarcoma. Veterinary Pathology, 2005, 42, 618-632.	1.7	71
31	A genome-wide approach to comparative oncology: high-resolution oligonucleotide aCGH of canine and human osteosarcoma pinpoints shared microaberrations. Cancer Genetics, 2012, 205, 572-587.	0.4	70
32	Characterization of canine osteosarcoma by array comparative genomic hybridization and RTâ€qPCR: Signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart. Genes Chromosomes and Cancer, 2011, 50, 859-874.	2.8	69
33	The Molecular Basis of Canine Melanoma: Pathogenesis and Trends in Diagnosis and Therapy. Journal of Veterinary Internal Medicine, 1999, 13, 163-174.	1.6	68
34	Identification of Three Molecular and Functional Subtypes in Canine Hemangiosarcoma through Gene Expression Profiling and Progenitor Cell Characterization. American Journal of Pathology, 2014, 184, 985-995.	3.8	68
35	Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer, 2010, 10, 619.	2.6	67
36	Expression of S100a, Vimentin, NSE, and Melan A/MART-1 in Seven Canine Melanoma Cell Lines and Twenty-nine Retrospective Cases of Canine Melanoma. Veterinary Pathology, 2001, 38, 427-435.	1.7	66

#	Article	IF	Citations
37	Pathobiology of Hemangiosarcoma in Dogs: Research Advances and Future Perspectives. Veterinary Sciences, 2015, 2, 388-405.	1.7	66
38	Genome-wide Association Study Identifies Shared Risk Loci Common to Two Malignancies in Golden Retrievers. PLoS Genetics, 2015, 11, e1004922.	3.5	66
39	Differential requirements for interleukin-2 distinguish the expression and activity of the cyclin-dependent kinases Cdk4 and Cdk2 in human T cells. Journal of Biological Chemistry, 1994, 269, 32972-32978.	3.4	59
40	Combinatorial Treatment of DNA and Chromatin-Modifying Drugs Cause Cell Death in Human and Canine Osteosarcoma Cell Lines. PLoS ONE, 2012, 7, e43720.	2.5	57
41	Genomic profiling reveals extensive heterogeneity in somatic DNA copy number aberrations of canine hemangiosarcoma. Chromosome Research, 2014, 22, 305-319.	2.2	54
42	Risk Factors for Development of Canine and Human Osteosarcoma: A Comparative Review. Veterinary Sciences, 2019, 6, 48.	1.7	54
43	Posttranscriptional Regulation of T-Cell IL-2 Production by Human Pooled Immunoglobin. Clinical Immunology and Immunopathology, 1997, 83, 77-85.	2.0	53
44	Bone Marrow Cytological Findings in 4 Dogs and a Cat With Hemophagocytic Syndrome. Journal of Veterinary Internal Medicine, 1996, 10, 7-14.	1.6	52
45	Construction of a 2-Mb resolution BAC microarray for CGH analysis of canine tumors. Genome Research, 2005, 15, 1831-1837.	5.5	51
46	Differential requirements for interleukin-2 distinguish the expression and activity of the cyclin-dependent kinases Cdk4 and Cdk2 in human T cells. Journal of Biological Chemistry, 1994, 269, 32972-8.	3.4	48
47	Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Molecular Cancer, 2007, 6, 16.	19.2	46
48	Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20. Cancer Immunology Research, 2016, 4, 1072-1087.	3.4	46
49	Inactivation of the p16 Cyclin-Dependent Kinase Inhibitor in High-Grade Canine Non-Hodgkin's T-Cell Lymphoma. Veterinary Pathology, 2007, 44, 467-478.	1.7	45
50	Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Therapy, 2003, 10, 726-736.	4.6	43
51	A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma. Veterinary Medicine and Science, 2016, 2, 179-190.	1.6	42
52	Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment. Experimental Cell Research, 2014, 323, 155-164.	2.6	41
53	Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential. Leukemia and Lymphoma, 2015, 56, 219-225.	1.3	39
54	Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis. BMC Cancer, 2017, 17, 67.	2.6	39

#	Article	IF	Citations
55	Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer. Oncotarget, 2016, 7, 66540-66557.	1.8	39
56	Inflammation, Apoptosis, and Necrosis Induced by Neoadjuvant Fas Ligand Gene Therapy Improves Survival of Dogs With Spontaneous Bone Cancer. Molecular Therapy, 2012, 20, 2234-2243.	8.2	38
57	Regulation of synthesis and activity of the PLSTIRE protein (cyclin-dependent kinase 6 (cdk6)), a major cyclin D-associated cdk4 homologue in normal human T lymphocytes. Journal of Immunology, 1995, 154, 6275-84.	0.8	38
58	Sustained nuclear localization of p21/WAF-1 upon growth arrest induced by contact inhibition. Cancer Letters, 2000, 158, 73-84.	7.2	37
59	Isolation and characterization of canine natural killer cells. Veterinary Immunology and Immunopathology, 2013, 155, 211-217.	1.2	36
60	Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma. Leukemia, 2007, 21, 184-187.	7.2	35
61	Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR. Molecular Cancer Therapeutics, 2017, 16, 956-965.	4.1	35
62	The Molecular Basis of Canine Melanoma: Pathogenesis and Trends in Diagnosis and Therapy. Journal of Veterinary Internal Medicine, 1999, 13, 163.	1.6	35
63	Growth Arrest of Melanoma Cells Is Differentially Regulated by Contact Inhibition and Serum Deprivation. DNA and Cell Biology, 1999, 18, 357-367.	1.9	34
64	Aberrant Retinoblastoma (RB)-E2F Transcriptional Regulation Defines Molecular Phenotypes of Osteosarcoma. Journal of Biological Chemistry, 2015, 290, 28070-28083.	3.4	34
65	Requirement for extracellular calcium or magnesium in mitogen-induced activation of human peripheral blood lymphocytes. Journal of Cellular Physiology, 1988, 135, 451-458.	4.1	32
66	Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors. International Journal of Cancer, 2013, 133, 1936-1944.	5.1	32
67	MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines. BMC Cancer, 2016, 16, 784.	2.6	32
68	Immunophysiological studies of interleukin-2 and canine lymphocytes. Veterinary Immunology and Immunopathology, 1992, 33, 1-16.	1.2	31
69	Hydroquinone and catechol interfere with T cell cycle entry and progression through the G1 phase. Molecular Immunology, 2003, 39, 995-1001.	2.2	31
70	Nicotine Activates Nuclear Factor of Activated T Cells c2 (NFATc2) and Prevents Cell Cycle Entry in T Cells. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 758-769.	2.5	31
71	The Use of Cytochemistry, Immunophenotyping, Flow Cytometry, and In Vitro Differentiation to Determine the Ontogeny of a Canine Monoblastic Leukemia. Veterinary Clinical Pathology, 1998, 27, 40-49.	0.7	29
72	Isolation of Cancer-Derived Exosomes Using a Variety of Magnetic Nanostructures: From Fe3O4 Nanoparticles to Ni Nanowires. Nanomaterials, 2020, 10, 1662.	4.1	29

#	Article	IF	Citations
73	Induction Of Lymphokine-Activated Killer (LAK) Activity in Canine Lymphocytes with Low Dose Human Recombinant Interleukin-2in vitro. Cancer Biotherapy, 1994, 9, 237-244.	0.5	28
74	CDK4 Expression and Activity Are Required for Cytokine Responsiveness in T Cells. Journal of Immunology, 2000, 165, 6693-6702.	0.8	28
75	Quantitative and Qualitative Signals Determine T-Cell Cycle Entry and Progression. Cellular Immunology, 1999, 197, 19-29.	3.0	26
76	Negative regulators in homeostasis of naÃ¯ve peripheral T cells. Immunologic Research, 2008, 41, 137-153.	2.9	26
77	Progesterone augments proliferation induced by epidermal growth factor in a feline mammary adenocarcinoma cell line. Journal of Cellular Biochemistry, 1991, 45, 196-206.	2.6	25
78	Nicotine-mediated signals modulate cell death and survival of T lymphocytes. Toxicology and Applied Pharmacology, 2010, 242, 299-309.	2.8	25
79	A Tumorâ€Related Lymphoid Progenitor Population Supports Hierarchical Tumor Organization in Canine Bâ€Cell Lymphoma. Journal of Veterinary Internal Medicine, 2011, 25, 890-896.	1.6	25
80	Functional Loss of p21/Waf-1 in a Case of Benign Canine Multicentric Melanoma. Veterinary Pathology, 1998, 35, 94-101.	1.7	24
81	Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure. Veterinary Sciences, 2015, 2, 363-387.	1.7	24
82	Chronic Nicotine Consumption Does Not Influence 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanoneâ€“Induced Lung Tumorigenesis. Cancer Prevention Research, 2011, 4, 1752-1760.	1.5	22
83	Potential to Target Dysregulated Interleukin-2 Receptor Expression in Canine Lymphoid and Hematopoietic Malignancies as a Model for Human Cancer. Journal of Immunotherapy, 2002, 25, 36-45.	2.4	21
84	Molecular characterization of canine <scp>BCR</scp>â€<scp>ABL</scp>â€“positive chronic myelomonocytic leukemia before and after chemotherapy. Veterinary Clinical Pathology, 2013, 42, 314-322.	0.7	20
85	Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy. Journal of Clinical Medicine, 2019, 8, 1802.	2.4	20
86	Retrovirus-like activity in an immunosuppressed dog: Pathological and immunological findings. Journal of Comparative Pathology, 1995, 112, 165-183.	0.4	19
87	Development of a Biolabeling System Using Ferromagnetic Nanowires. IEEE Journal of Electromagnetics, RF and Microwaves in Medicine and Biology, 2019, 3, 134-142.	3.4	18
88	Protein kinase C regulates both production and secretion of interleukin 2. Journal of Biological Chemistry, 1991, 266, 10552-61.	3.4	18
89	CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool forin vitropreclinical studies with primary B-cell malignancies. Leukemia and Lymphoma, 2012, 53, 1390-1398.	1.3	17
90	Alignment of collagen matrices using magnetic nanowires and magnetic barcode readout using first order reversal curves (FORC) (invited). Journal of Magnetism and Magnetic Materials, 2018, 459, 176-181.	2.3	17

#	Article	IF	Citations
91	Interactions between <scp>CXCR4</scp> and <scp>CXCL12</scp> promote cell migration and invasion of canine hemangiosarcoma. Veterinary and Comparative Oncology, 2017, 15, 315-327.	1.8	16
92	Evaluation of 18-F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) as a staging and monitoring tool for dogs with stage-2 splenic hemangiosarcoma â€“ A pilot study. PLoS ONE, 2017, 12, e0172651.	2.5	16
93	Symmetry of the Activation of Cyclin-dependent Kinases in Mitogen and Growth Factor-stimulated T Lymphocytes. Annals of the New York Academy of Sciences, 1995, 766, 134-148.	3.8	15
94	A Bayesian adaptive Phase Iâ€“II clinical trial for evaluating efficacy and toxicity with delayed outcomes. Clinical Trials, 2014, 11, 38-48.	1.6	15
95	Stimulation with Concanavalin-A Induces IL-17 Production by Canine Peripheral T Cells. Veterinary Sciences, 2015, 2, 43-51.	1.7	15
96	Association of Sphingosineâ€1â€phosphate (S1P)/S1P Receptorâ€1 Pathway with Cell Proliferation and Survival in Canine Hemangiosarcoma. Journal of Veterinary Internal Medicine, 2015, 29, 1088-1097.	1.6	15
97	Heterotypic models of osteosarcoma recapitulate tumor heterogeneity and biological behavior. DMM Disease Models and Mechanisms, 2016, 9, 1435-1444.	2.4	15
98	Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS ONE, 2020, 15, e0224775.	2.5	15
99	Nfatc2 and Tob1 Have Non-Overlapping Function in T Cell Negative Regulation and Tumorigenesis. PLoS ONE, 2014, 9, e100629.	2.5	14
100	Selective Detection of Cancer Cells Using Magnetic Nanowires. ACS Applied Materials & Interfaces, 2021, 13, 21060-21066.	8.0	14
101	Biomonitoring the Cooked Meat Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Canine Fur. Journal of Agricultural and Food Chemistry, 2012, 60, 9371-9375.	5.2	12
102	Stage-specific embryonic antigen: determining expression in canine glioblastoma, melanoma, and mammary cancer cells. Journal of Veterinary Science, 2017, 18, 101.	1.3	12
103	Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions. Molecular Cancer Research, 2021, 19, 847-861.	3.4	12
104	Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade. Melanoma Research, 2020, 30, 147-158.	1.2	12
105	Fas ligand based immunotherapy: A potent and effective neoadjuvant with checkpoint inhibitor properties, or a systemically toxic promoter of tumor growth?. Discovery Medicine, 2016, 21, 109-16.	0.5	12
106	Use of the Cellâ€Dyn 3500 to Predict Leukemic Cell Lineage in Peripheral Blood of Dogs and Cats. Veterinary Clinical Pathology, 2002, 31, 167-182.	0.7	11
107	Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells. Clinical Immunology, 2004, 112, 54-65.	3.2	11
108	Immunotherapy with autologous tumour antigenâ€coated microbeads (large multivalent immunogen), ILâ€2 and GMâ€CSF in dogs with spontaneous Bâ€cell lymphoma. Veterinary and Comparative Oncology, 2011, 9, 95-105.	1.8	11

#	Article	IF	Citations
109	Enrichment and Quantification of Epitope-specific CD4+ T Lymphocytes using Ferromagnetic Iron-gold and Nickel Nanowires. Scientific Reports, 2018, 8, 15696.	3.3	11
110	Increased risk of cancer in dogs and humans: A consequence of recent extension of lifespan beyond evolutionarily determined limitations?. Aging and Cancer, 2022, 3, 3-19.	1.6	11
111	Pharmacological Inhibition of Cyclin Dependent Kinases Causes p53 Dependent Apoptosis in Renal Cell Carcinoma. Journal of Urology, 2010, 184, 2143-2149.	0.4	10
112	Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies. Leukemia and Lymphoma, 2017, 58, 1702-1710.	1.3	10
113	Retrospective evaluation of thrombocytopenia and tumor stage as prognostic indicators in dogs with splenic hemangiosarcoma. Journal of the American Veterinary Medical Association, 2021, 258, 630-637.	0.5	10
114	Mammary Mass Aspirate from a Yorkshire Terrier. Veterinary Clinical Pathology, 1998, 27, 79-92.	0.7	9
115	Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer. Human Gene Therapy Clinical Development, 2017, 28, 80-86.	3.1	9
116	A comparison of risk factors for metastasis at diagnosis in humans and dogs with osteosarcoma. Cancer Medicine, 2019, 8, 3216-3226.	2.8	9
117	Comparative Approach to the Temporo-Spatial Organization of the Tumor Microenvironment. Frontiers in Oncology, 2019, 9, 1185.	2.8	9
118	Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors. Biomolecules, 2020, 10, 956.	4.0	9
119	Extracellular Vesicles Secreted by Tumor Cells Promote the Generation of Suppressive Monocytes. ImmunoHorizons, 2021, 5, 647-658.	1.8	9
120	Anti-Insulin Immune Responses Are Detectable in Dogs with Spontaneous Diabetes. PLoS ONE, 2016, 11, e0152397.	2.5	8
121	Modulation of fatty acid metabolism and immune suppression are features of in vitro tumour sphere formation in ontogenetically distinct dog cancers. Veterinary and Comparative Oncology, 2018, 16, E176-E184.	1.8	8
122	Arginase Treatment Prevents the Recovery of Canine Lymphoma and Osteosarcoma Cells Resistant to the Toxic Effects of Prolonged Arginine Deprivation. PLoS ONE, 2013, 8, e54464.	2.5	8
123	Clues to immune function and oncogenesis provided by events that activate the cell cycle machinery in normal human T cells. Journal of Leukocyte Biology, 1997, 62, 430-437.	3.3	7
124	Impact of repeated cycles of EGF bispecific angiotoxin (eBAT) administered at a reduced interval from doxorubicin chemotherapy in dogs with splenic haemangiosarcoma. Veterinary and Comparative Oncology, 2020, 18, 664-674.	1.8	7
125	MHC-dependent desensitization of intrinsic anti-self reactivity. Cancer Immunology, Immunotherapy, 2009, 58, 171-185.	4.2	6
126	Exclusion of cytoplasmic fragments in flow cytometric analysis of lymph node samples from dogs with lymphoma using membrane-permeable violet laser-excitable DNA-binding fluorescent dye (DyeCycle Violet). Veterinary Clinical Pathology, 2010, 39, 494-498.	0.7	6

#	Article	IF	Citations
127	Applicability of 3T Body <scp>MRI</scp> in Assessment of Nonfocal Bone Marrow Involvement of Hematopoietic Neoplasia in Dogs. Journal of Veterinary Internal Medicine, 2013, 27, 1165-1171.	1.6	6
128	Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment. Cancer Immunology, Immunotherapy, 2015, 64, 1449-1460.	4.2	6
129	Comparative Pathogenesis of Cancers in Animals and Humans. Veterinary Sciences, 2016, 3, 24.	1.7	6
130	Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells. Frontiers in Immunology, 2022, 13, 841859.	4.8	6
131	Polymorphisms within the Telomerase Reverse Transcriptase gene (TERT) in four breeds of dogs selected for difference in lifespan and cancer susceptibility. BMC Veterinary Research, 2014, 10, 20.	1.9	5
132	Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors. Veterinary and Comparative Oncology, 2015, 13, 48-59.	1.8	5
133	Evaluation of protein kinase CK2 as a therapeutic target for squamous cell carcinoma of cats. American Journal of Veterinary Research, 2017, 78, 946-953.	0.6	5
134	Ectodomain shedding by ADAM17 (a disintegrin and metalloproteinase 17) in canine neutrophils. Veterinary Immunology and Immunopathology, 2021, 231, 110162.	1.2	5
135	Realizing the Principles for Remote and Selective Detection of Cancer Cells Using Magnetic Nanowires. Journal of Physical Chemistry B, 2021, 125, 7742-7749.	2.6	5
136	Development of an exosomal gene signature to detect residual disease in dogs with osteosarcoma using a novel xenograft platform and machine learning. Laboratory Investigation, 2021, 101, 1585-1596.	3.7	5
137	Parenchymal signal intensity in 3-T body MRI of dogs with hematopoietic neoplasia. Comparative Medicine, 2013, 63, 174-82.	1.0	5
138	Functional interleukin-2 receptors are expressed on natural killer-like leukemic cells from a dog with cutaneous lymphoma. Blood, 1995, 86, 636-45.	1.4	5
139	Comparative analysis of genome-wide DNA methylation identifies patterns that associate with conserved transcriptional programs in osteosarcoma. Bone, 2022, 158, 115716.	2.9	4
140	Results of a Phase I Dose Escalation Study of the Novel, Oral CRM1 Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Spontaneous Non-Hodgkin's Lymphomas (NHL). Blood, 2012, 120, 161-161.	1.4	4
141	A double blinded, placebo-controlled pilot study to examine reduction of CD34+/CD117+/CD133+ lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma. F1000Research, 2015, 4, 42.	1.6	4
142	Early changes in metabolism of leukemic cell lines upon induction of apoptosis by cytotoxic drugs. European Journal of Pharmacology, 2003, 465, 23-30.	3.5	3
143	Establishment of a Patient-Derived Xenograft of Canine Enteropathy-Associated T-Cell Lymphoma, Large Cell Type. Journal of Comparative Pathology, 2017, 156, 37-41.	0.4	3
144	A double blinded, placebo-controlled pilot study to examine reduction of CD34+/CD117+/CD133+ lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma. F1000Research, 0, 4, 42.	1.6	3

#	Article	IF	Citations
145	A double blinded, placebo-controlled pilot study to examine reduction of CD34+/CD117+/CD133+ lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma. F1000Research, 2015, 4, 42.	1.6	3
146	Abstract 3809: Evaluation of the novel, orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in spontaneous canine cancer: Results of phase I and phase II clinical trials. Cancer Research, 2014, 74, 3809-3809.	0.9	2
147	Abstract 817: Unbiased discovery of exosome-associated biomarkers using xenograft models. Cancer Research, 2017, 77, 817-817.	0.9	2
148	Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer. Kidney360, 2020, 1, 376-388.	2.1	2
149	Bioapplications of Magnetic Nanowires: Barcodes, Biocomposites, Heaters. IEEE Transactions on Magnetics, 2022, 58, 1-6.	2.1	2
150	Targeted sequencing of candidate gene regions for myelofibrosis in dogs. Journal of Veterinary Internal Medicine, 0, , .	1.6	2
151	INITIAL EVALUATION OF SAFETY OF WIDE-FIELD IRRADIATION IN THE TREATMENT OF HEMATOPOIETIC NEOPLASIA IN THE CAT. Veterinary Radiology and Ultrasound, 2010, 51, 688-696.	0.9	1
152	Combination radioimmunotherapy with adoptive NK transfer targets cancer stem cells in canine models of bone and soft tissue sarcoma. , 2015, 3, .		1
153	Abstract LB-086: Combination therapy of immune checkpoint and nuclear exporter inhibitors in a renal cell carcinoma mouse model. , 2016, , .		1
154	Abstract 5357: Mutational and transcriptomic profiling identify distinct angiogenic and inflammatory subtypes of angiosarcoma. , 2018, , .		1
155	Abstract A51: Quality control and quality assurance of canine biological specimens available through the Pfizer-CCOGC, Inc. National Biorepository for Comparative Oncology Studies. , 2014, , .		1
156	Binding of VEGF-A to canine cancer cells with preferential expression of VEGFR1. Veterinary World, 2014, 7, 1-6.	1.7	1
157	Abstract B19: RB function as a central component of osteosarcoma behavior: A comparative assessment in dogs and humans. , 2014, , .		1
158	Hemangiosarcoma and its cancer stem cell sub-population are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors. BMC Proceedings, 2013, 7, .	1.6	0
159	S100A4 mRNA-protein relationship uncovered by measurement noise reduction. Journal of Molecular Medicine, 2020, 98, 735-749.	3.9	0
160	Abstract LB-432: Effect of chronic nicotine consumption on NNK-induced lung tumors in the A/J mouse. , 2011, , .		0
161	Abstract 184: Breed-associated differential microRNA expression in canine osteosarcoma. , 2012, , .		0
162	Abstract 3482: Validation of novel therapeutic targets for T-cell non-Hodgkin lymphoma. , 2012, , .		0

#	Article	IF	Citations
163	Abstract 4082: CD47 blockade to enhance adaptive anti-tumor immune responses. , 2014, , .		0
164	Abstract 540: Characterization of miR-9 expression and activation in canine osteosarcoma. , 2014, , .		0
165	Abstract 1694: Preclinical evaluation of a novel bispecific targeted toxin for the treatment of sarcomas. , 2015, , .		0
166	Abstract A143: Melanoma cell resistance to phagocytosis is unrelated to expression of conventional â€œeat-me/don't eat-meâ€•signals. , 2016, , .		0
167	Abstract A65: Mechanisms of melanoma cell resistance to phagocytosis. , 2017, , .		0
168	Abstract 2264: RNA sequencing based analysis of transposon-induced tumors reveals novel insights into cancer pathogenesis and progression. , 2018, , .		0
169	Abstract 3399: Comparative genomic analyses of osteosarcoma etiology reveal a chromosomal structural rationale for the increased incidence of osteosarcoma in dogs. , 2018, , .		0
170	Abstract 824: Targeting epidermal growth factor receptors and urokinase-type plasminogen activator receptors for sarcoma therapy. , 2018, , .		0
171	Abstract 1341: Magnetic isolation and identification of exosomes using Fe/Au nanowires. , 2019, , .		0
172	Abstract 3715: Cancer as a consequence of breaking through evolutionary constraints on longevity. , 2019, , .		0
173	Title is missing!. , 2020, 15, e0224775.		0
174	Title is missing!. , 2020, 15, e0224775.		0
175	Title is missing!. , 2020, 15, e0224775.		0
176	Title is missing!. , 2020, 15, e0224775.		0